In a report issued early Thursday morning, the independent Presidential Commission for the Study of Bioethical Issues warned that whole genome sequencing – likely available in the near future for as little as $1,000 – could raise enormous ethical dilemmas not only in patient care but also in the conduct of clinical trials.